OncoCyte Corporation
OncoCyte Corporation (OCX) Financial Performance & Income Statement Overview
Explore the financials of OncoCyte Corporation (OCX), including yearly and quarterly data on income, cash flow, and balance sheets.
OncoCyte Corporation (OCX) Income Statement & Financial Overview
View the income breakdown for OncoCyte Corporation OCX across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $2.14M | $1.49M | $115000.00 | $104000.00 |
| Cost of Revenue | $813000.00 | $511000.00 | $65000.00 | $54000.00 |
| Gross Profit | $1.32M | $595000.00 | $50000.00 | $50000.00 |
| Gross Profit Ratio | $0.62 | $0.40 | $0.43 | $0.48 |
| R&D Expenses | $2.92M | $1.92M | $2.82M | $2.45M |
| SG&A Expenses | $4.32M | $3.40M | $3.61M | $3.26M |
| Operating Expenses | $7.31M | $34.22M | $13.56M | $5.71M |
| Total Costs & Expenses | $8.12M | $36.42M | $13.63M | $5.77M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | -$29000.00 | $30000.00 | $31000.00 | $8000.00 |
| Depreciation & Amortization | $0.00 | $563000.00 | $340000.00 | $326000.00 |
| EBITDA | -$6.80M | -$32.92M | -$13.52M | -$4.20M |
| EBITDA Ratio | -$3.18 | -$22.15 | -$117.52 | -$40.35 |
| Operating Income | -$6.80M | -$33.63M | -$13.52M | -$4.63M |
| Operating Income Ratio | -$3.18 | -$22.63 | -$117.52 | -$44.54 |
| Other Income/Expenses (Net) | $128000.00 | $116000.00 | $22000.00 | $102000.00 |
| Income Before Tax | -$6.67M | -$33.51M | -$13.49M | -$4.53M |
| Income Before Tax Ratio | -$3.12 | -$22.55 | -$117.33 | -$43.56 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$6.67M | -$33.51M | -$13.49M | -$4.53M |
| Net Income Ratio | -$3.12 | -$22.55 | -$117.33 | -$43.56 |
| EPS | -$25.96 | -$1.93 | -$0.98 | -$0.36 |
| Diluted EPS | -$25.96 | -$1.93 | -$0.98 | -$0.36 |
| Weighted Avg Shares Outstanding | $256940.00 | $13.07M | $13.71M | $12.87M |
| Weighted Avg Shares Outstanding (Diluted) | $256940.00 | $13.07M | $13.71M | $12.87M |
Over the last four quarters, OncoCyte Corporation's revenue moved from $104000.00 in Q2 2024 to $2.14M in Q1 2025. Operating income in Q1 2025 was -$6.80M, with a strong operating margin of -318%. Despite fluctuations in R&D and SG&A expenses, EBITDA for OncoCyte Corporation remained robust at -$6.80M, reflecting operational efficiency. Net income rose to -$6.67M, with an EPS of -$25.96. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan